A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning the biotech to seek approval of the microbiome therapy in Europe in mid-2025.
MaaT Pharma is racing its microbiome therapy into a late-phase cancer clinical trial. Rather than take the current phase 1b to its planned conclusion, MaaT is wrapping the trial up early to accelerate ...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for ...
In June 2025, the European Medicines Agency accepted for review the marketing authorization submission for this medicine MaaT Pharma will receive a €10.5 million upfront payment, further potential ...
Tranche-based financing to support clinical development for the Company’s late-stage assets in hemato-oncology including Xervyteg ® currently under review for potential approval by the EMA and MaaT033 ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
LYON, France--(BUSINESS WIRE)--Regulatory News: These encouraging findings from the IASO Phase 1b trial confirm the favorable safety and tolerability profile of MaaT033 in ALS patients. They also ...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results